These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1154 related articles for article (PubMed ID: 17762437)

  • 41. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience.
    Machtay M; Hsu C; Komaki R; Sause WT; Swann RS; Langer CJ; Byhardt RW; Curran WJ
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):667-71. PubMed ID: 15927409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
    Spencer SA; Harris J; Wheeler RH; Machtay M; Schultz C; Spanos W; Rotman M; Meredith R; Ang KK
    Head Neck; 2008 Mar; 30(3):281-8. PubMed ID: 17764087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention.
    Mehta V
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):5-24. PubMed ID: 15963660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients.
    Ozkok S; Karakoyun-Celik O; Goksel T; Mogulkoc N; Yalman D; Gok G; Bolukbasi Y
    Lung Cancer; 2008 Dec; 62(3):326-33. PubMed ID: 18482780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome.
    van der Voort van Zyp NC; Prévost JB; Hoogeman MS; Praag J; van der Holt B; Levendag PC; van Klaveren RJ; Pattynama P; Nuyttens JJ
    Radiother Oncol; 2009 Jun; 91(3):296-300. PubMed ID: 19297048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer.
    Narayan S; Henning GT; Ten Haken RK; Sullivan MA; Martel MK; Hayman JA
    Lung Cancer; 2004 Apr; 44(1):79-88. PubMed ID: 15013586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results.
    Graham MV; Pajak TE; Herskovic AM; Emami B; Perez CA
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):819-25. PubMed ID: 7860394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk?
    Hoppe BS; Laser B; Kowalski AV; Fontenla SC; Pena-Greenberg E; Yorke ED; Lovelock DM; Hunt MA; Rosenzweig KE
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1283-6. PubMed ID: 19028267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation?
    Chen M; Hayman JA; Ten Haken RK; Tatro D; Fernando S; Kong FM
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):120-6. PubMed ID: 16198503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The quantitative evaluation of the serum acute phase proteins (APP) of patients undergoing a curative resection for non-small cell lung cancer (NSCLC)].
    Kasprzyk M; Dyszkiewicz W; Zwaruń D; Szydlik S; Leśniewska K; Krzyzanowski M
    Przegl Lek; 2006; 63(10):936-40. PubMed ID: 17288188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
    Jeremić B; Milicić B
    Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer.
    Werner-Wasik M; Swann RS; Bradley J; Graham M; Emami B; Purdy J; Sause W
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):385-90. PubMed ID: 17869017
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study.
    Shennib H; Bogart J; Herndon JE; Kohman L; Keenan R; Green M; Sugarbaker D; ;
    J Thorac Cardiovasc Surg; 2005 Apr; 129(4):813-8. PubMed ID: 15821648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The radiotherapy of inoperable non-small-cell bronchial carcinoma. A retrospective analysis of 427 cases].
    Würschmidt F; Bünemann H; Bünemann C; Beck-Bornholdt HP; Heilmann HP
    Strahlenther Onkol; 1994 May; 170(5):302-4. PubMed ID: 8197553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radiation therapy alone in early stage non-small cell lung cancer.
    Zimmermann FB; Bamberg M; Molls M; Jeremic B
    Semin Surg Oncol; 2003; 21(2):91-7. PubMed ID: 14508859
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.
    Xia T; Li H; Sun Q; Wang Y; Fan N; Yu Y; Li P; Chang JY
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):117-25. PubMed ID: 16765528
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.
    Ricardi U; Filippi AR; Guarneri A; Giglioli FR; Mantovani C; Fiandra C; Anglesio S; Ragona R
    Acta Oncol; 2009; 48(4):571-7. PubMed ID: 19031164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma proteomic analysis may identify new markers for radiation-induced lung toxicity in patients with non-small-cell lung cancer.
    Cai XW; Shedden K; Ao X; Davis M; Fu XL; Lawrence TS; Lubman DM; Kong FM
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):867-76. PubMed ID: 20510197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.